Skip to main content

Main menu

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • RESOURCES
    • About BJGP
    • Conference
    • Advertising
    • BJGP Life
    • eLetters
    • Librarian information
    • Alerts
    • Resilience
    • Video
    • Audio
    • COVID-19 Clinical Solutions
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
    • RCGP e-Portfolio

User menu

  • Subscriptions
  • Alerts
  • Log in

Search

  • Advanced search
British Journal of General Practice
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
    • RCGP e-Portfolio
  • Subscriptions
  • Alerts
  • Log in
  • Follow bjgp on Twitter
  • Visit bjgp on Facebook
  • Blog
  • Listen to BJGP podcast
Advertisement
British Journal of General Practice

Advanced Search

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • RESOURCES
    • About BJGP
    • Conference
    • Advertising
    • BJGP Life
    • eLetters
    • Librarian information
    • Alerts
    • Resilience
    • Video
    • Audio
    • COVID-19 Clinical Solutions
Clinical Intelligence

How to manage low testosterone level in men: a guide for primary care

Ahmed Al-Sharefi, Scott Wilkes, Channa N Jayasena and Richard Quinton
British Journal of General Practice 2020; 70 (696): 364-365. DOI: https://doi.org/10.3399/bjgp20X710729
Ahmed Al-Sharefi
Section of Investigative Medicine, Hammersmith Hospital, Imperial College London, London.
Roles: Specialty registrar in diabetes & endocrinology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Wilkes
University of Sunderland, Sunderland.
Roles: Professor of general practice & primary care and head of School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Channa N Jayasena
Section of Investigative Medicine, Hammersmith Hospital, Imperial College London, London.
Roles: Clinical senior lecturer and consultant in reproductive endocrinology & andrology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Quinton
Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne.
Roles: Senior Lecturer & Consultant in Endocrinology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info
  • eLetters
  • PDF
Loading

Published eLetters

eLetter submission guidelines

Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Jump to comment:

  • How to manage low testosterone level in men: a guide for primary care
    Geoffrey Hackett, Professor Mike Kirby, David Ralph, Sudarshan Ramachandran, Rowland Rees, T Hugh Jones, Jonny Coxon, Adrian Heald and Patrick Wright
    Published on: 03 July 2020
  • How to manage low testosterone level in men: a guide for primary care
    George Castle
    Published on: 27 June 2020
  • Published on: (3 July 2020)
    How to manage low testosterone level in men: a guide for primary care
    • Geoffrey Hackett, Consultant in Urology, Aston University
    • Other Contributors:
      • Professor Mike Kirby, Physician, University of Hertfordshire
      • David Ralph, Consultant Urologist, UCH London
      • Sudarshan Ramachandran, Professor of Metabolic Medicine, Keele University
      • Rowland Rees, Urologist, University Hospital Southampton
      • T Hugh Jones, Consultant Endocrinologist, University of Sheffield
      • Jonny Coxon, Gender physician / President BSSM, British Society for sexual Medicine
      • Adrian Heald, Consultant in Diabetes, University of Manchester
      • Patrick Wright, GP, BSSM
    We write on behalf of the British Society for Sexual Medicine to express our concerns over the above “clinical intelligence” or “guide” for general practitioners on male hypogonadism and the accompanying management algorithm. We are concerned that this terminology made lead to GPs interpreting the article as being a peer reviewed guideline rather than personal opinion. Unfortunately, the authors state that there are UK guidelines in place for erectile dysfunction, referencing a guideline of fertility and a NHS clinical knowledge summary Aug 2019, which comes with a disclaimer that it is NOT a NICE guideline. In fact, this NHS CKS states that is almost exclusively based on the comprehensive peer reviewed BSSM guidelines 2018,1 omitted by the authors, who chose to reference Australian guidelines instead. The guidelines of the American Urology Association state that “patients need to be informed that low testosterone is an independent risk factor for cardiovascular disease”.2 
     
    Whilst we could dissect many points in the article that are not referenced and represent personal opinion, we believe that the findings from 2 pivotal trials should lead the authors reconsider their advice. Firstly, the recent T4DM RCT3 involving 1007 obese men with hypogonadism studied for 2 years, presented at American Diabetes Association 2020, clearly showed that TRT reduces progressi...
    Show More
    We write on behalf of the British Society for Sexual Medicine to express our concerns over the above “clinical intelligence” or “guide” for general practitioners on male hypogonadism and the accompanying management algorithm. We are concerned that this terminology made lead to GPs interpreting the article as being a peer reviewed guideline rather than personal opinion. Unfortunately, the authors state that there are UK guidelines in place for erectile dysfunction, referencing a guideline of fertility and a NHS clinical knowledge summary Aug 2019, which comes with a disclaimer that it is NOT a NICE guideline. In fact, this NHS CKS states that is almost exclusively based on the comprehensive peer reviewed BSSM guidelines 2018,1 omitted by the authors, who chose to reference Australian guidelines instead. The guidelines of the American Urology Association state that “patients need to be informed that low testosterone is an independent risk factor for cardiovascular disease”.2 
     
    Whilst we could dissect many points in the article that are not referenced and represent personal opinion, we believe that the findings from 2 pivotal trials should lead the authors reconsider their advice. Firstly, the recent T4DM RCT3 involving 1007 obese men with hypogonadism studied for 2 years, presented at American Diabetes Association 2020, clearly showed that TRT reduces progression to type 2 diabetes by over 40% compared with intensive lifestyle intervention. In fact, 2 years of free weightwatcher intervention with one to one support, despite moderate weight loss, resulted in worsening of physical symptoms. Based on NHS diabetes figures, the T4DM study results suggests that, with their cut-off of 14 nmol/l for total testosterone and BMI of over 30 kg/m2, over 1 million men in the UK could potentially be prevented from progressing to type 2 diabetes. In the T4DM study, TRT v lifestyle advice and placebo, resulted in significantly greater loss of visceral fat, increase in muscle mass and symptomatic benefit. This paper is likely to change clinical practice. We acknowledge the findings of this were not available at the time that this paper went to press.
     
    The second, and most important study to date is the T trial4 of 780 hypogonadal men using testosterone gel v placebo over 12 months. This showed conclusively that TRT significantly improved sexual function, depression, mood, walking distance, anaemia, and bone mineral density. Both these large RCTs included men almost exclusively classified as “functional hypogonadism” and provide the highest level of evidence. Apart from bariatric surgery, multiple meta-analyses have shown lifestyle interventions alone in male hypogonadism do not improve clinical symptoms.5 Quinton et al. comment that the management of non-gonadal illness “should not usually involve testosterone” is not supported by a large body of evidence. Distressing clinical symptoms bring the patient to the doctor, not a desire for body sculpture as suggested by the authors.
     
    We would invite the authors to address these issues of clinical evidence as we feel that this “guide” will cause great confusion for many general practitioners.
     
    References
    1. Hackett G, Kirby M, Edwards D et al. British Society for Sexual Medicine guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med 2017; 14:1504-23.
    2. Mulhall JP, Trost LW, Brannigan RE et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol 2018; 200(2):423–432. doi:10.1016/j.juro.2018.03.115 
    3. Wittert G, Atlantis E, Bracken AC et al. Effect of Testosterone treatment on Type 2 diabetes Incidence in high risk men enrolled in a Lifestyle programme: 2-year Randomised placebo-controlled study: presentation 274-OR. American Diabetes Association  June 2020.
    4. Snyder PJ, Bhasin S, Cunningham GR et al. Effects of Testosterone Treatment in Older Men. N Engl J Med 2016; 374(7):611-24.
    5.  Giagulli VA,  Castellana M,  Lisco G  Triggiani V. Critical evaluation of different available guidelines for late‐onset hypogonadism.  Andrology. 27 June 2020 https://doi.org/10.1111/andr.12850.
     
    Show Less
    Competing Interests: None declared.
  • Published on: (27 June 2020)
    How to manage low testosterone level in men: a guide for primary care
    • George Castle, Foundation Doctor, York Teaching Hospital NHS Trust
    Al-Sharefi et al1 correctly identify that there is currently some debate about the correct monitoring of testosterone replacement therapy in primary care.
    In comparison to the many drug monitoring activities carried out to high standards in General Practice, such as rheumatological DMARD immunosuppressives, or therapies linked to the QOF domains like levothyroxine, there may be under-performance in the monitoring of testosterone replacement therapy (TRT). As is the case for many long-term conditions in primary care, practice nurses and clinical pharmacists could become more involved in this.
     
    In a preliminary study2 that we performed in two typical practices in the East of England, it was clear that patients were not consistently receiving the recommended annual monitoring, in particular PSA testing and digital rectal examination (DRE).
     
    There are multiple reasons for this, including the disparity between the different international guidelines and the absence of a UK consensus. The patients are often unaware, as the leaflets inside their medication do not highlight monitoring requirements. When patients are discharged from endocrinology or urology clinics for follow-up by general practitioners, the communication of explicit guidance on the requisite monitoring would be helpful to both doctor and patient.
     
    Further work is needed to set agree...
    Show More
    Al-Sharefi et al1 correctly identify that there is currently some debate about the correct monitoring of testosterone replacement therapy in primary care.
    In comparison to the many drug monitoring activities carried out to high standards in General Practice, such as rheumatological DMARD immunosuppressives, or therapies linked to the QOF domains like levothyroxine, there may be under-performance in the monitoring of testosterone replacement therapy (TRT). As is the case for many long-term conditions in primary care, practice nurses and clinical pharmacists could become more involved in this.
     
    In a preliminary study2 that we performed in two typical practices in the East of England, it was clear that patients were not consistently receiving the recommended annual monitoring, in particular PSA testing and digital rectal examination (DRE).
     
    There are multiple reasons for this, including the disparity between the different international guidelines and the absence of a UK consensus. The patients are often unaware, as the leaflets inside their medication do not highlight monitoring requirements. When patients are discharged from endocrinology or urology clinics for follow-up by general practitioners, the communication of explicit guidance on the requisite monitoring would be helpful to both doctor and patient.
     
    Further work is needed to set agreed UK GP guidelines for the monitoring of testosterone replacement therapy, including DRE guidance, plus education on the risks of TRT; and the organising of regular practice audit is desirable to ensure that regular reviews in primary care are taking place.
     
    References
    1. Al-Sharefi A, Wilkes S, Jayasena CN, Quinton R. How to manage low testosterone level in men: a guide for primary care.  Br J Gen Pract 2020; 70 (696): 364-365.
    2. Castle G, Stammers J. Testosterone Prescribing in UK General Practice: Are patients being monitored correctly for associated risks whilst on treatment? Basic & Clinical Pharmacology & Toxicology 2020 May 30. doi.org/10.1111/bcpt.13448.
     
    Show Less
    Competing Interests: None declared.
Back to top
Previous ArticleNext Article

In this issue

British Journal of General Practice: 70 (696)
British Journal of General Practice
Vol. 70, Issue 696
July 2020
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Or,
sign in or create an account with your email address
Email Article

Thank you for recommending British Journal of General Practice.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How to manage low testosterone level in men: a guide for primary care
(Your Name) has forwarded a page to you from British Journal of General Practice
(Your Name) thought you would like to see this page from British Journal of General Practice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
How to manage low testosterone level in men: a guide for primary care
Ahmed Al-Sharefi, Scott Wilkes, Channa N Jayasena, Richard Quinton
British Journal of General Practice 2020; 70 (696): 364-365. DOI: 10.3399/bjgp20X710729

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
How to manage low testosterone level in men: a guide for primary care
Ahmed Al-Sharefi, Scott Wilkes, Channa N Jayasena, Richard Quinton
British Journal of General Practice 2020; 70 (696): 364-365. DOI: 10.3399/bjgp20X710729
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • INTRODUCTION
    • DIAGNOSTIC CHALLENGES
    • PRIMARY, SECONDARY, AND FUNCTIONAL HYPOGONADISM
    • MANAGEMENT GUIDELINES
    • SAFETY OF TESTOSTERONE AND OTHER CONSIDERATIONS
    • WHAT IT MEANS FOR GENERAL PRACTICE
    • SUMMARY
    • Notes
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info
  • eLetters
  • PDF

More in this TOC Section

  • Hyperparathyroidism (primary) NICE guideline: diagnosis, assessment, and initial management
  • The atypical presentation of COVID-19 as gastrointestinal disease: key points for primary care
  • COVID-19 with abdominal symptoms and acute abdominal pain: a guide to identification for general practice
Show more Clinical Intelligence

Related Articles

Cited By...

Advertisement

BJGP Life

BJGP Open

 

@BJGPjournal's Likes on Twitter

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Current Issue
  • All Issues
  • Online First
  • Authors & reviewers

RCGP

  • BJGP for RCGP members
  • BJGP Open
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers
  • RCGP e-Portfolio

MY ACCOUNT

  • RCGP members' login
  • Subscriber login
  • Activate subscription
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP: research
  • Writing for BJGP: other sections
  • BJGP editorial process & policies
  • BJGP ethical guidelines
  • Peer review for BJGP

CUSTOMER SERVICES

  • Advertising
  • Contact subscription agent
  • Copyright
  • Librarian information

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7679
Email: journal@rcgp.org.uk

British Journal of General Practice is an editorially-independent publication of the Royal College of General Practitioners
© 2021 British Journal of General Practice

Print ISSN: 0960-1643
Online ISSN: 1478-5242